Certain SARS-CoV-2 patients produce exceptionally potent and versatile antibodies that neutralize the virus and multiple variants, according to leading research.
Scientists have dubbed this phenomenon "superhuman immunity" or "bulletproof immunity." Immunologist Shane Crotty, in a June 2021 Science article, termed it "hybrid immunity," highlighting its remarkable potency against SARS-CoV-2.
Recent studies, including one from Rockefeller University's Laboratory of Molecular Immunology in June 2021, reveal that some COVID-19 patients generate extraordinarily high antibody levels with broad versatility. These antibodies remain effective against circulating variants and may combat emerging ones.
Dr. Paul Bieniasz, involved in the June study, pre-published new findings on BioRxiv on August 8, 2021. Speaking to NPR, he described antibodies that neutralize six related coronaviruses, including Delta and Beta variants, pangolin and bat viruses, and SARS-CoV-1 from the 2003 outbreak.
"Optimally obtained human polyclonal antibodies against SARS-CoV-2 should resist substantial future variations and could protect against future sarbecovirus pandemics," states the lead researcher.
While somewhat speculative pending peer review, Dr. Bieniasz believes these patients gain protection against novel SARS-like viruses. This work could guide preparations for variants and future coronavirus outbreaks. Meanwhile, global health authorities emphasize vaccination as the most effective path to ending the pandemic and restoring normalcy.
